Merck and Moderna’s long-standing 50/50 collaboration on the intismeran autogene mRNA cancer vaccine with Keytruda has produced sustained positive data, including a 49% recurrence risk reduction at five years from Phase 2b and encouraging initial Phase 3 melanoma results released August 19, 2026. These outcomes heighten the strategic value of the asset for Merck as it targets $70 billion in sales by the mid-2030s to offset Keytruda’s 2028 patent cliff. At the same time, Merck’s recent M&A has favored smaller bolt-on deals, such as the $6.7 billion Terns acquisition, while Moderna remains independent with expanding trials across multiple indications. This equilibrium of proven partnership upside versus limited signals of full-company acquisition talks sustains the even 50% implied probability. Further Phase 3 readouts, regulatory progress, or explicit merger discussions could shift odds sharply in either direction.
Experimental AI-generated summary referencing Polymarket data. This is not trading advice and plays no role in how this market resolves. · Updated28% chance
NEW
NEW
Dec 31, 2026
28% chance
NEW
NEW
Dec 31, 2026
This market will resolve to "Yes" if it is officially announced that Merck & Co. (MRK) will be, has been, or is being acquired by or merged with Moderna (MRNA), or vice versa, by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
A qualifying merger or acquisition must encompass both MRK and MRNA or their subsidiaries.
An announcement by MRK or MRNA within this market's timeframe will qualify for a "Yes" resolution, regardless of whether or when the announced acquisition/merger actually occurs.
A bid or offer announcement without the indication of a settled agreement will not qualify.
Announcements of partial sales may count, as long as the acquiring company announces the acquisition of a controlling interest in the other company. A "controlling interest" refers to a change in ownership sufficient to control the company's strategic decisions (typically more than 50% of equity, or equivalent control via voting and governance rights). Transactions or investments that do not result in a transfer of controlling interest will not count.
The primary resolution source for this market will be official information from MRK and MRNA; however, a consensus of credible reporting may also be used.Merck and Moderna’s long-standing 50/50 collaboration on the intismeran autogene mRNA cancer vaccine with Keytruda has produced sustained positive data, including a 49% recurrence risk reduction at five years from Phase 2b and encouraging initial Phase 3 melanoma results released August 19, 2026. These outcomes heighten the strategic value of the asset for Merck as it targets $70 billion in sales by the mid-2030s to offset Keytruda’s 2028 patent cliff. At the same time, Merck’s recent M&A has favored smaller bolt-on deals, such as the $6.7 billion Terns acquisition, while Moderna remains independent with expanding trials across multiple indications. This equilibrium of proven partnership upside versus limited signals of full-company acquisition talks sustains the even 50% implied probability. Further Phase 3 readouts, regulatory progress, or explicit merger discussions could shift odds sharply in either direction.
This market will resolve to "Yes" if it is officially announced that Merck & Co. (MRK) will be, has been, or is being acquired by or merged with Moderna (MRNA), or vice versa, by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
A qualifying merger or acquisition must encompass both MRK and MRNA or their subsidiaries.
An announcement by MRK or MRNA within this market's timeframe will qualify for a "Yes" resolution, regardless of whether or when the announced acquisition/merger actually occurs.
A bid or offer announcement without the indication of a settled agreement will not qualify.
Announcements of partial sales may count, as long as the acquiring company announces the acquisition of a controlling interest in the other company. A "controlling interest" refers to a change in ownership sufficient to control the company's strategic decisions (typically more than 50% of equity, or equivalent control via voting and governance rights). Transactions or investments that do not result in a transfer of controlling interest will not count.
The primary resolution source for this market will be official information from MRK and MRNA; however, a consensus of credible reporting may also be used.
A qualifying merger or acquisition must encompass both MRK and MRNA or their subsidiaries.
An announcement by MRK or MRNA within this market's timeframe will qualify for a "Yes" resolution, regardless of whether or when the announced acquisition/merger actually occurs.
A bid or offer announcement without the indication of a settled agreement will not qualify.
Announcements of partial sales may count, as long as the acquiring company announces the acquisition of a controlling interest in the other company. A "controlling interest" refers to a change in ownership sufficient to control the company's strategic decisions (typically more than 50% of equity, or equivalent control via voting and governance rights). Transactions or investments that do not result in a transfer of controlling interest will not count.
The primary resolution source for this market will be official information from MRK and MRNA; however, a consensus of credible reporting may also be used.
Market Opened: Aug 19, 2026, 3:58 PM ET
Volume
$0End Date
Dec 31, 2026Market Opened
Aug 19, 2026, 3:58 PM ETResolver
0x65070BE91...This market will resolve to "Yes" if it is officially announced that Merck & Co. (MRK) will be, has been, or is being acquired by or merged with Moderna (MRNA), or vice versa, by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
A qualifying merger or acquisition must encompass both MRK and MRNA or their subsidiaries.
An announcement by MRK or MRNA within this market's timeframe will qualify for a "Yes" resolution, regardless of whether or when the announced acquisition/merger actually occurs.
A bid or offer announcement without the indication of a settled agreement will not qualify.
Announcements of partial sales may count, as long as the acquiring company announces the acquisition of a controlling interest in the other company. A "controlling interest" refers to a change in ownership sufficient to control the company's strategic decisions (typically more than 50% of equity, or equivalent control via voting and governance rights). Transactions or investments that do not result in a transfer of controlling interest will not count.
The primary resolution source for this market will be official information from MRK and MRNA; however, a consensus of credible reporting may also be used.Merck and Moderna’s long-standing 50/50 collaboration on the intismeran autogene mRNA cancer vaccine with Keytruda has produced sustained positive data, including a 49% recurrence risk reduction at five years from Phase 2b and encouraging initial Phase 3 melanoma results released August 19, 2026. These outcomes heighten the strategic value of the asset for Merck as it targets $70 billion in sales by the mid-2030s to offset Keytruda’s 2028 patent cliff. At the same time, Merck’s recent M&A has favored smaller bolt-on deals, such as the $6.7 billion Terns acquisition, while Moderna remains independent with expanding trials across multiple indications. This equilibrium of proven partnership upside versus limited signals of full-company acquisition talks sustains the even 50% implied probability. Further Phase 3 readouts, regulatory progress, or explicit merger discussions could shift odds sharply in either direction.
This market will resolve to "Yes" if it is officially announced that Merck & Co. (MRK) will be, has been, or is being acquired by or merged with Moderna (MRNA), or vice versa, by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
A qualifying merger or acquisition must encompass both MRK and MRNA or their subsidiaries.
An announcement by MRK or MRNA within this market's timeframe will qualify for a "Yes" resolution, regardless of whether or when the announced acquisition/merger actually occurs.
A bid or offer announcement without the indication of a settled agreement will not qualify.
Announcements of partial sales may count, as long as the acquiring company announces the acquisition of a controlling interest in the other company. A "controlling interest" refers to a change in ownership sufficient to control the company's strategic decisions (typically more than 50% of equity, or equivalent control via voting and governance rights). Transactions or investments that do not result in a transfer of controlling interest will not count.
The primary resolution source for this market will be official information from MRK and MRNA; however, a consensus of credible reporting may also be used.
A qualifying merger or acquisition must encompass both MRK and MRNA or their subsidiaries.
An announcement by MRK or MRNA within this market's timeframe will qualify for a "Yes" resolution, regardless of whether or when the announced acquisition/merger actually occurs.
A bid or offer announcement without the indication of a settled agreement will not qualify.
Announcements of partial sales may count, as long as the acquiring company announces the acquisition of a controlling interest in the other company. A "controlling interest" refers to a change in ownership sufficient to control the company's strategic decisions (typically more than 50% of equity, or equivalent control via voting and governance rights). Transactions or investments that do not result in a transfer of controlling interest will not count.
The primary resolution source for this market will be official information from MRK and MRNA; however, a consensus of credible reporting may also be used.
Volume
$0End Date
Dec 31, 2026Market Opened
Aug 19, 2026, 3:58 PM ETResolver
0x65070BE91...Merck and Moderna’s long-standing 50/50 collaboration on the intismeran autogene mRNA cancer vaccine with Keytruda has produced sustained positive data, including a 49% recurrence risk reduction at five years from Phase 2b and encouraging initial Phase 3 melanoma results released August 19, 2026. These outcomes heighten the strategic value of the asset for Merck as it targets $70 billion in sales by the mid-2030s to offset Keytruda’s 2028 patent cliff. At the same time, Merck’s recent M&A has favored smaller bolt-on deals, such as the $6.7 billion Terns acquisition, while Moderna remains independent with expanding trials across multiple indications. This equilibrium of proven partnership upside versus limited signals of full-company acquisition talks sustains the even 50% implied probability. Further Phase 3 readouts, regulatory progress, or explicit merger discussions could shift odds sharply in either direction.
Experimental AI-generated summary referencing Polymarket data. This is not trading advice and plays no role in how this market resolves. · Updated
Beware of external links.
Beware of external links.
Frequently Asked Questions